Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.

Pagliuca M, Buonerba C, Fizazi K, Di Lorenzo G.

Drugs. 2019 Mar;79(4):381-400. doi: 10.1007/s40265-019-1060-5. Review.

PMID:
30742279
2.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
3.

Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies.

Patel NK, Finianos A, Whitaker KD, Aragon-Ching JB.

Ther Clin Risk Manag. 2014 Aug 16;10:651-64. doi: 10.2147/TCRM.S57509. eCollection 2014. Review.

4.

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.

Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16. Review.

PMID:
29673712
5.

Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, Dearnaley D, Parker C, de Bono JS, Attard G.

Eur Urol. 2014 Sep;66(3):459-65. doi: 10.1016/j.eururo.2013.11.044. Epub 2013 Dec 17.

PMID:
24411987
6.

Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Kearns B, Pandor A, Stevenson M, Hamilton J, Chambers D, Clowes M, Graham J, Kumar MS.

Pharmacoeconomics. 2017 Apr;35(4):415-424. doi: 10.1007/s40273-016-0457-1. Review.

7.

New drugs in prostate cancer.

Yoo S, Choi SY, You D, Kim CS.

Prostate Int. 2016 Jun;4(2):37-42. doi: 10.1016/j.prnil.2016.05.001. Epub 2016 May 17. Review.

8.

Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy.

Omlin A, Pezaro C, Gillessen Sommer S.

Ther Adv Urol. 2014 Feb;6(1):3-14. doi: 10.1177/1756287213509677. Review.

9.

Castration-resistant prostate cancer: from new pathophysiology to new treatment.

Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F.

Eur Urol. 2014 Feb;65(2):289-99. doi: 10.1016/j.eururo.2013.08.008. Epub 2013 Aug 11. Review.

PMID:
23957948
10.

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.

J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. Review.

PMID:
26196735
11.

Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223.

Mukherji D, El Dika I, Temraz S, Haidar M, Shamseddine A.

Ther Clin Risk Manag. 2014 May 23;10:373-80. doi: 10.2147/TCRM.S45667. eCollection 2014. Review.

12.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.

Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.

PMID:
27591931
13.

[New therapy concepts for castration-resistant prostate cancer: between hormone manipulation, targeted therapy and chemotherapy].

Kübler H, Miller K.

Urologe A. 2013 Nov;52(11):1517-8, 1520-1, 1524-6 passim. doi: 10.1007/s00120-013-3247-9. Review. German.

PMID:
24166056
14.

Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.

Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ; Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.

Clin Oncol (R Coll Radiol). 2013 Jul;25(7):406-30. doi: 10.1016/j.clon.2013.03.002. Epub 2013 Apr 12. Review.

PMID:
23587782
15.

Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer.

Semenas J, Dizeyi N, Persson JL.

Drug Des Devel Ther. 2013 Aug 27;7:875-81. doi: 10.2147/DDDT.S45703. eCollection 2013. Review.

16.

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?

Bitting RL, Armstrong AJ, George DJ.

Clin Med Insights Oncol. 2011;5:325-32. doi: 10.4137/CMO.S5977. Epub 2011 Oct 20.

17.

Management of metastatic castration-resistant prostate cancer.

Antonarakis ES.

Eur Urol Rev. 2011 Winter;6(2):90-96.

18.

A changing landscape in castration-resistant prostate cancer treatment.

Felici A, Pino MS, Carlini P.

Front Endocrinol (Lausanne). 2012 Jul 18;3:85. doi: 10.3389/fendo.2012.00085. eCollection 2012.

19.

The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.

Saad F, Sternberg CN, Mulders PFA, Niepel D, Tombal BF.

Cancer Treat Rev. 2018 Jul;68:25-37. doi: 10.1016/j.ctrv.2018.04.014. Epub 2018 May 3. Review.

20.

Sequencing of agents for castration-resistant prostate cancer.

Hurwitz M, Petrylak DP.

Oncology (Williston Park). 2013 Nov;27(11):1144-9, 1154-8. Review.

Supplemental Content

Support Center